Cancidas (caspofungin acetate) for Injection, for Intravenous Use
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)
April 2016
ADVERSE REACTIONS
Postmarketing Experience
… toxic epidermal necrolysis…Stevens-Johnson syndrome…
...
Source: Drugs.com - Labeling Changes - Category: Drugs & Pharmacology Source Type: alerts